Effect of Hepatic Impairment on the Pharmacokinetics of a Single Dose of TD-9855
Status:
Completed
Trial end date:
2021-08-19
Target enrollment:
Participant gender:
Summary
An open-label study to characterize the effects of mild, moderate, and severe Hepatic
Impairment (HI) on the pharmacokinetics (PK) of ampreloxetine following a single oral dose in
comparison with healthy volunteers with normal hepatic function.